Letters Safety of new oral anticoagulants

Effective antidotes for new anticoagulants

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2775 (Published 26 May 2015) Cite this as: BMJ 2015;350:h2775
  1. Mark Lythgoe, clinical fellow1
  1. 1Imperial College, Hammersmith Hospital, London W12 0HS, UK
  1. Mark.Lythgoe{at}nhs.net

Sarrazin and Rose discuss the safety profiles of the anticoagulants rivaroxaban and dabigatran but do not include the most recent developments in reversing their effects.1

Idarucizumab is a monoclonal antibody that can immediately reverse the effects …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe